Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis

NASDAQ:ABEO - Nasdaq - US00289Y2063 - Common Stock - Currency: USD

5.78  -0.04 (-0.69%)

Fundamental Rating

2

Overall ABEO gets a fundamental rating of 2 out of 10. We evaluated ABEO against 571 industry peers in the Biotechnology industry. While ABEO seems to be doing ok healthwise, there are quite some concerns on its profitability. ABEO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ABEO had negative earnings in the past year.
ABEO had a negative operating cash flow in the past year.
ABEO had negative earnings in each of the past 5 years.
ABEO had a negative operating cash flow in each of the past 5 years.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

ABEO has a Return On Assets (-58.90%) which is comparable to the rest of the industry.
ABEO has a worse Return On Equity (-155.18%) than 65.95% of its industry peers.
Industry RankSector Rank
ROA -58.9%
ROE -155.18%
ROIC N/A
ROA(3y)-86.37%
ROA(5y)-69.79%
ROE(3y)-230.99%
ROE(5y)-163.57%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABEO has been increased compared to 1 year ago.
ABEO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ABEO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -8.04, we must say that ABEO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.04, ABEO is not doing good in the industry: 70.05% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.31 indicates that ABEO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.31, ABEO is not doing good in the industry: 72.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -8.04
ROIC/WACCN/A
WACC9.51%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

ABEO has a Current Ratio of 6.12. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ABEO (6.12) is better than 61.85% of its industry peers.
ABEO has a Quick Ratio of 6.12. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ABEO (6.12) is better than 62.21% of its industry peers.
Industry RankSector Rank
Current Ratio 6.12
Quick Ratio 6.12
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

5

3. Growth

3.1 Past

ABEO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -478.05%.
ABEO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
The Revenue has been growing slightly by 3.13% on average over the past years.
EPS 1Y (TTM)-478.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.25%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-29.53%
Revenue growth 5Y3.13%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ABEO will show a very strong growth in Earnings Per Share. The EPS will grow by 28.76% on average per year.
ABEO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 139.27% yearly.
EPS Next Y36.47%
EPS Next 2Y24.24%
EPS Next 3Y22.78%
EPS Next 5Y28.76%
Revenue Next Year-96.43%
Revenue Next 2Y137.71%
Revenue Next 3Y178.89%
Revenue Next 5Y139.27%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABEO. In the last year negative earnings were reported.
Also next year ABEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ABEO's earnings are expected to grow with 22.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.24%
EPS Next 3Y22.78%

More info and screens

0

5. Dividend

5.1 Amount

ABEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (2/21/2025, 8:00:00 PM)

5.78

-0.04 (-0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-17 2025-03-17/amc
Inst Owners76.5%
Inst Owner Change-96.64%
Ins Owners7.23%
Ins Owner Change19.7%
Market Cap251.26M
Analysts84
Price Target16.22 (180.62%)
Short Float %6.16%
Short Ratio9.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)49.15%
Min EPS beat(2)-52.88%
Max EPS beat(2)151.17%
EPS beat(4)1
Avg EPS beat(4)-20.97%
Min EPS beat(4)-121.54%
Max EPS beat(4)151.17%
EPS beat(8)4
Avg EPS beat(8)25.36%
EPS beat(12)6
Avg EPS beat(12)14.41%
EPS beat(16)9
Avg EPS beat(16)7.84%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.07%
PT rev (3m)-0.1%
EPS NQ rev (1m)-0.71%
EPS NQ rev (3m)6.58%
EPS NY rev (1m)0.31%
EPS NY rev (3m)-8.21%
Revenue NQ rev (1m)25%
Revenue NQ rev (3m)25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-37.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.49
P/tB 5.49
EV/EBITDA N/A
EPS(TTM)-2.37
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0
BVpS1.05
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.9%
ROE -155.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.37%
ROA(5y)-69.79%
ROE(3y)-230.99%
ROE(5y)-163.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.82%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.12
Quick Ratio 6.12
Altman-Z -8.04
F-Score1
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)47.42%
Cap/Depr(5y)50.94%
Cap/Sales(3y)52.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-478.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.25%
EPS Next Y36.47%
EPS Next 2Y24.24%
EPS Next 3Y22.78%
EPS Next 5Y28.76%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-29.53%
Revenue growth 5Y3.13%
Sales Q2Q%N/A
Revenue Next Year-96.43%
Revenue Next 2Y137.71%
Revenue Next 3Y178.89%
Revenue Next 5Y139.27%
EBIT growth 1Y-29.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.5%
OCF growth 3YN/A
OCF growth 5YN/A